Addex Therapeutics (ADXN) Stock Price
Addex Therapeutics Price
Revenue at Addex Therapeutics has contracted by 23.4% per year over the past 19 years to 35,894.09 USD. Addex Therapeutics's net margin stands at -22,448.4%, down from -526.4% several years earlier.
Addex Therapeutics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Addex Therapeutics business model & stock analysis
Frequently asked questions about Addex Therapeutics
9 analysts currently rate the Addex Therapeutics stock: 0 recommend buying, 2 holding and 7 selling.
Converted at the current exchange rate, the Addex Therapeutics share trades at 2.69 EUR (3.02 USD).
The expected revenue of Addex Therapeutics is 1.80 M USD. This figure is based on current financial data and reflects the company's business performance.
The profit cannot currently be calculated for Addex Therapeutics.
The P/E ratio cannot be calculated for Addex Therapeutics at the moment.
The price-to-sales ratio (P/S) of Addex Therapeutics is currently 1.99. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Addex Therapeutics stock.
The Eulerpool Quality Score for Addex Therapeutics is 2/10.
The ISIN of Addex Therapeutics is US00654J2069. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Addex Therapeutics is ADXN. The ticker symbol is used to trade Addex Therapeutics shares on the stock exchange.
Addex Therapeutics stock
Addex Therapeutics Peer Group
All fundamentals and in-depth analysis of Addex Therapeutics
Our stock analysis for Addex Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Addex Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.